Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Invitae Corporation    NVTA

INVITAE CORPORATION

(NVTA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
01/21/2021 01/22/2021 01/25/2021 01/26/2021 01/27/2021 Date
53.13(c) 55.21(c) 52.23(c) 48.15(c) 47.69(c) Last
3 667 897 6 372 787 4 905 958 4 427 372 5 347 178 Volume
-6.67% +3.91% -5.40% -7.81% -0.96% Change
More quotes
Financials (USD)
Sales 2020 278 M - -
Net income 2020 -428 M - -
Net Debt 2020 36,9 M - -
P/E ratio 2020 -14,6x
Yield 2020 -
Sales 2021 463 M - -
Net income 2021 -268 M - -
Net Debt 2021 132 M - -
P/E ratio 2021 -30,0x
Yield 2021 -
Capitalization 9 091 M 9 091 M -
EV / Sales 2020 32,8x
EV / Sales 2021 19,9x
Nbr of Employees 1 900
Free-Float 78,9%
More Financials
Company
Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. As of December 31, 2016, the Company's products consisted of assays totaling over 1,100 genes that could be used for... 
More about the company
Notations Surperformance© of Invitae Corporation
Trading Rating : Investor Rating :
More Ratings
All news about INVITAE CORPORATION
01/26INVITAE CORP : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
01/26INVITAE : Announces Exercise in Full of Underwriters' Option to Purchase Additio..
PR
01/22SECTOR UPDATE : Health Care Stocks Sputter Late, Drift Back Near Friday Starting..
MT
01/22SECTOR UPDATE : Slim Advance for Health Care Stocks Amid Biotech Rebound
MT
01/22INVITAE : Prices $400 Million Public Offering
MT
01/21INVITAE : Announces Pricing of Public Offering of Common Stock
PR
01/20INVITAE CORP : Results of Operations and Financial Condition, Other Events, Fina..
AQ
01/20Invitae Plans $400 Million Share Offering -- Stock Down 3.5% After-Hours
MT
01/20INVITAE : Announces Proposed Public Offering of Common Stock
PR
01/14Invitae to Develop Standardized Panel to Detect Molecular Residual Disease as..
MT
01/14INVITAE : Leading Biopharmaceutical Companies Select Invitae to Develop Standard..
PR
01/13PACIFIC BIOSCIENCES OF CALIFORNIA : Signs Collaboration Deal With Invitae to Dev..
MT
01/13INVITAE : Pacific Biosciences and Invitae to Develop Ultra-High-Throughput Clini..
AQ
01/12INVITAE : JP Morgan 2021 presentation
PU
01/12INVITAE : Oppenheimer Adjusts Price Target for Invitae to $51 From $48, Maintain..
MT
More news
News in other languages on INVITAE CORPORATION
01/11STRATÉGIE : les quatre meilleurs fonds US 2020
2020DPA-AFX-ÜBERBLICK : UNTERNEHMEN vom 24.06.2020 - 15.15 Uhr
2020Qiagen winkt hoher Sondergewinn aus Verkauf einer US-Beteiligung
2020Aktien Frankfurt Ausblick: Moderate Verluste erwartet
2020KORREKTUR : Qiagen winkt hoher Sondergewinn durch Verkauf von US-Beteiligung
More news
Analyst Recommendations on INVITAE CORPORATION
More recommendations
Chart INVITAE CORPORATION
Duration : Period :
Invitae Corporation Technical Analysis Chart | NVTA | US46185L1035 | MarketScreener
Technical analysis trends INVITAE CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 51,25 $
Last Close Price 47,69 $
Spread / Highest target 34,2%
Spread / Average Target 7,46%
Spread / Lowest Target -14,0%
EPS Revisions
Managers and Directors
NameTitle
Sean Emerson George Chairman, President & Chief Executive Officer
Kenneth D. Knight Chief Operating Officer
Shelly D. Guyer Chief Financial Officer
Robert Nussbaum Chief Medical Officer
Eric I. Aguiar Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
INVITAE CORPORATION14.06%9 091
EXACT SCIENCES CORPORATION3.29%21 763
GUARDANT HEALTH, INC.14.36%14 735
BGI GENOMICS CO., LTD.31.71%9 694
ADAPTIVE BIOTECHNOLOGIES CORPORATION-7.59%7 473
IOVANCE BIOTHERAPEUTICS, INC.-8.23%6 246